Drug Scheduling Actions

Proposed Rule: Placement of Carisoprodol Into Schedule IV (November 17, 2009)

Proposed Rule: Placement of 5-Methoxy-N,N-Dimethyltryptamine Into Schedule I of the Controlled Substances Act (October 28, 2009)

Final Rule: Placement of Fospropofol Into Schedule IV (October 6, 2009)

Proposed Rule: Placement of 5-Methoxy-N,N-Dimethyltryptamine Into Schedule I (August 21, 2009)

Proposed Rule: Placement of Fospropofol Into Schedule IV (July 23, 2009)

Final Rule: Placement of Tapentadol Into Schedule II (May 21, 2009)

Final Rule: Placement of Lacosamide into Schedule V (May 21, 2009)

Proposed Rule: Placement of Lacosamide into Schedule V (March 10, 2009)

Proposed Rule: Placement of Tapentadol Into Schedule II (February 17, 2009)

Anabolic Steroids

Final Rule: Classification of Three Steroids as Schedule III Anabolic Steroids Under the Controlled Substances Act (December 4, 2009)

General

Proposed Rule: Identification of Institution-based Individual Practitioners (September 9, 2009)

Interim Rule With Request for Comments: Table of Excluded Nonnarcotic Products: Nasal Decongestant Inhalers Manufactured by Classic Pharmaceuticals LLC (August 28, 2009)

Interim Final Rule With Request for Comments: Implementation of the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 (PDF) (April 6, 2009)

Proposed Rule: Disposal of Controlled Substances by Persons Not Registered With the Drug Enforcement Administration (January 21, 2009)

Registration

Proposed Rule: Registration Requirements for Individual Practitioners Operating in a "Locum Tenens" Capacity (October 28, 2009)

NOTICE: This is an unofficial version. An official version of this publication may be obtained directly from the Government Publishing Office (GPO).